; Juniper Pharmaceuticals | Press Releases

Press Releases

2017 | 2016 | 2015 | 2014 | 2013

Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results

CRINONE® Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization BOSTON, Nov. 2, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a diversified healthcare company focused on women's health, today announced fin...

Read More

Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017

Conference Call Scheduled for 4:30 p.m. EDT BOSTON, Oct. 26, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on November 2, 2017, to discuss the financial results for the third quarter ended September 30, 2017, ...

Read More

Juniper Pharmaceuticals Announces Strategic Reprioritization

- Changes Designed to Drive Continued Growth in Core Businesses of Crinone® and Juniper Pharma Services, Focus R&D Strategy - BOSTON, Sept. 18, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics company, today announced a corporate reprioritization to ...

Read More

Juniper Pharmaceuticals Appoints Jennifer Good to Board of Directors

- Board of Directors accepts resignation of Frank Armstrong - BOSTON, Sept. 11, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics company, today announced the appointment of Jennifer Good to the Company's Board of Directors. Ms. Good will serve as a membe...

Read More

Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results

CRINONE® Revenues Increased 30% and Juniper Pharma Services Revenues increase 30% Year-over-Year BOSTON, Aug. 3, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics company, today announced financial results for the three-month period ended June 30, 2017. C...

Read More

Juniper Pharmaceuticals to Report Second Quarter 2017 Results on August 3, 2017

Conference Call Scheduled for 4:30 p.m. EST BOSTON, July 27, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on August 3, 2017, to discuss the financial results for the second quarter ended June 30, 2017, as follows: Date: ...

Read More

Juniper Pharmaceuticals Announces Results of 2017 Annual Meeting

BOSTON, July 5, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced the results of its Annual Meeting of Shareholders held in Boston on June 30, 2017. Six of the seven mem...

Read More

Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating Results

Revenue from Core Business Increased 17% Year-over-Year CRINONE® Revenues Increased 22% and Juniper Pharma Services Revenues Rose 25% in Local Currency Compared to First Quarter of 2016 BOSTON, May 4, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics c...

Read More

Juniper Pharmaceuticals to Report First Quarter 2017 Results on May 4, 2017

Conference Call Scheduled for 8:30 a.m. EST BOSTON, April 28, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on May 4, 2017, to discuss the financial results for the first quarter ended March 31, 2017, as follows: ...

Read More

Juniper Pharmaceuticals Recognized for Board Diversity at Get Konnected! 9th Anniversary Event

BOSTON, March 29, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that it has been recognized as one of greater Boston's 15 companies with the most diverse boards, the GK15.  The Company accepted the awar...

Read More

Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

Revenue from Core Business Increased 17% Year-over-Year Plan to File Three INDs in the First Half of 2018 Remains on Track Conference Call at 8:30 a.m. EST Today BOSTON, March 7, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's healt...

Read More

Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017

BOSTON, March 6, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Alicia Secor, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference as follows:   ...

Read More

Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017

-- Conference Call Scheduled for 8:30 a.m. EST -- BOSTON, March 1, 2017 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 7, 2017, to discuss the financial results for the fourth quarter and twel...

Read More

Juniper Pharmaceuticals Presents Poster at SMFM 2017 on Current Practice Among U.S. Obstetricians to Screen, Define, and Treat a Short Cervix to Prevent Preterm Birth

Physician Survey Demonstrates Need for an Approved Vaginal Progesterone Product Juniper is Advancing Its Investigational Progesterone Intravaginal Ring to Treat Women at Risk for Preterm Birth due to Short Cervix BOSTON, Jan. 26, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("J...

Read More

Juniper Pharmaceuticals Unveils Strategic and Product Development Objectives for 2017

Juniper Advancing IVR Pipeline while Actively Pursuing Partnering Opportunities Aligned with Mission to Transform Women's Health BOSTON, Jan. 6, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") today announced plans for 2017 that are expected to enab...

Read More

Juniper Pharmaceuticals Announces Poster Presentation at Society for Maternal-Fetal Medicine 2017 Annual Meeting

BOSTON, Jan. 5, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that an abstract describing data exploring current practices among U.S. obstetricians to screen, define, and treat a short cervix...

Read More